Connect with us

Technology

Medidata Launches Medidata Plus, an AI-Native Foundation Built to Scale Clinical Portfolios

Published

on

Built on an award-winning AI foundation, Medidata Plus removes traditional barriers, empowering sponsors and CROs to scale intelligence across entire portfolios

SINGAPORE, July 30, 2026 /PRNewswire/ — Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today announced the launch of Medidata Plus. This clinical artificial intelligence layer unlocks the full breadth of AI capabilities across the Medidata Platform, giving sponsors access to scalable, outcome-driven AI throughout their global portfolios. Medidata Plus shifts the life sciences industry away from a legacy of disjointed, inefficient point solutions to a unified, end-to-end AI strategy, accelerating the delivery of life-saving therapies to patients.

While 92% of industry decision-makers plan to increase AI investment, only 29% say AI currently meets or exceeds their expectations. Medidata Plus addresses these systemic roadblocks directly, turning unpredictable AI costs into a streamlined, predictable investment by standardizing the data layer across the entire clinical trial lifecycle.

“Stitching together point solutions isn’t a strategy — it’s a liability. Drug development’s next leap will come when AI is consistent, connected, and portfolio-wide,” said Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC. “Medidata Plus delivers this with a cohesive AI layer across the entire lifecycle, shifting organizations from sporadic AI adoption to a continuous, portfolio-wide strategy that drives real clinical outcomes.” 

Medidata Plus brings AI-driven intelligence to every stage of a clinical trial, from study build to data management to ongoing risk monitoring. Rather than relying on a patchwork of disconnected tools, study teams can access a single, unified layer of AI capabilities built to accelerate execution and surface insights in real time. Key capabilities made accessible through Medidata Plus include:

Study Builds Accelerated with AI: Reduces study build timelines from weeks to mere hours by automating EDC and eCOA design, and generating synthetic patient data for user acceptance testing, dramatically accelerating study startup times.No-Code Data Transformation: Through enhanced AI interoperability, Medidata Plus seamlessly ingests, standardizes, and transforms data from clinical and real-world sources to extract insights without writing a single line of code.Proactive De-risking: Embedded analytics instantly flag critical enrollment downtrends or safety signals, reducing mid-cycle pauses and accelerating inspections.Companioning Audit Exploration: Agentic AI supports study teams to mine their end-to-end audit history using natural-language queries, transforming complex regulatory data into actionable insights in minutes.

“We’ve listened to our customers and they’re clear that AI can transform clinical trials, but not as an army of agents from disparate sources trained in disparate ways,” said Anthony Costello, CEO, Medidata. “Medidata Plus is a drop-in AI strategy for clinical research that upskills teams, automates workflows, and surfaces insights at a pace that’s redefining what teams thought was possible. We are in conversations with dozens of customers about making this shift and what we’re hearing tells us the industry has been waiting for exactly this.”

Life sciences organizations, ranging from enterprise biopharma leaders to global CROs, are poised to unlock significant value through Medidata Plus, which provides them with a decisive technological edge to execute clinical trials with greater precision, higher quality, and accelerated timelines. 

The launch of Medidata Plus establishes a future-ready framework for platform advancement. As Medidata continues to embed clinically-fluent AI across its ecosystem, study teams from sponsors and CROs will gain access to an expanding suite of capabilities that deliver value across their trial portfolios.

Backed by an AI infrastructure recently recognized with the highest “Luminary” rating in Everest Group’s AI Innovation Watch Report, Medidata’s AI continues to set the standard in clinical trials, having supported 80% of FDA novel drug approvals in 2025. To learn more about how Medidata Plus delivers an easy, fast, and AI-powered clinical research experience, visit here

About Medidata 

Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata’s Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn. 

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. Through the 3DEXPERIENCE platform, AI-powered, science-based virtual twins help 390,000 customers of all sizes, in all industries, collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com

Contact:  

For interviews and questions, please contact Medidata PR 

Medidata.PR@3ds.com  

Analyst Relations 

Medidata.AR@3ds.com  

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/medidata-launches-medidata-plus-an-ai-native-foundation-built-to-scale-clinical-portfolios-302838472.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

XCMG’s First Overseas New Energy Factory Commences Production in Indonesia

Published

on

By

WEDA, Indonesia, July 30, 2026 /PRNewswire/ — XCMG (SHE: 000425) held an inauguration ceremony for its Indonesia New Energy Manufacturing Base (the “Base”) on July 27 at Indonesia Weda Bay Industrial Park (IWIP) in North Maluku Province. With the first batch of new energy equipment rolling off the production line and being delivered to strategic partner Tsingshan Holding Group’s IWIP, XCMG’s first overseas new energy factory commenced production.

XCMG is accelerating its five-pronged transformation toward high-end, intelligent, green, global and service-oriented development, with global operations and green industrial development as two core strategic priorities. The launch of XCMG’s first overseas new energy factory represents a strategic move integrating these priorities.

The Base integrates complete equipment manufacturing, localized R&D tailored to operating conditions, and local services, shortening delivery lead times and serving applications across Indonesia’s mining, infrastructure and industrial park logistics sectors.

Leveraging local smart manufacturing capabilities, the Base enables the large-scale supply of electric construction machinery to support the low-carbon transition of key industries in Indonesia. XCMG is developing a used-equipment circulation and parts remanufacturing system to maximize resource efficiency.

The delivery of the first batch of new energy equipment demonstrates a collaborative model between XCMG and IWIP that combines technology with application scenarios and manufacturing with market demand. Drawing on XCMG’s expertise in intelligent new energy manufacturing and IWIP’s industrial ecosystem and application scenarios, the two parties completed construction and commenced production in a short timeframe. The cross-sector collaboration also offers a new model for global partnerships among Chinese enterprises.

With over 30 years in Indonesia, XCMG has built a comprehensive localized business and service system comprising a network of sales and service outlets, more than 100 specialized service vehicles, and a three-tier spare parts and maintenance support system, ensuring the reliable operation of more than 30,000 units of XCMG equipment across the country.

The commissioning of the plant completes XCMG’s integrated R&D, production, supply, sales and service chain in Indonesia. Locally manufactured new energy equipment is poised to become a key pillar supporting the high-quality development of green infrastructure in the country.

Local employees account for nearly 80% of XCMG’s workforce in Indonesia, while the Group continues to create jobs and develop skilled talent. In 2026, XCMG Machinery was again named to the Fortune China ESG Impact List, remaining the only construction machinery company on the list.

SOURCE XCMG Machinery

Continue Reading

Technology

Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore’s Position as Asia’s Franchise and Licensing Hub

Published

on

By

SINGAPORE, July 30, 2026 /PRNewswire/ — Franchising & Licensing Asia (FLAsia) 2026 will launch on the 13–15 August at the Marina Bay Sands Expo & Convention Centre, marking a significant milestone as the event enters its 21st edition under the organisation of MP Singapore.

Presented by the Franchising and Licensing Association (FLA) (Singapore), FLAsia 2026 brings together more than 250 international franchise and licensable brands, over 150 exhibitors from across Asia and beyond, and is expected to welcome more than 7,000 business leaders, investors, entrepreneurs and decision-makers over three days.

The event will be opened by our guest-of-honour, Ms Low Yen Ling, Senior Minister of State for the Ministry of Trade and Industry and the Ministry of Culture, Community and Youth.

Gan Shee Wen, President, Franchising and Licensing Association (Singapore) added:

“For over two decades, FLAsia has supported countless businesses in their growth journeys. This year’s edition reflects the growing confidence in Asia’s franchising ecosystem and reinforces Singapore’s position as the region’s gateway for brands looking to expand internationally.”

“Singapore is well positioned for business expansion in the Asia region. As Asia’s Leading Franchise and Licensing event, FLAsia has always been more than an exhibition—it is a marketplace where entrepreneurs, investors and brands come together to create new opportunities. MP Singapore is committed to elevating FLAsia into Asia’s premier platform for business expansion, bringing together global brands, innovative concepts and strategic partnerships that will shape the future of franchising and licensing.”, stated Jason Ng, Managing Director, MP Group

A Vibrant Marketplace for Regional Growth & Expansion

This year’s event will feature franchise and licensing brands across several industry sectors, including:

Beauty & WellnessEducationFood & BeverageIntellectual Property & LicensingLifestyleRetailServicesTechnology

Beyond the exhibition, visitors can also participate in an extensive programme comprising:

2nd Chinese Franchise Summit2nd Edition: Design WAH!Business Matching ProgrammeCreative Capital Conference: Design x IP & LicensingExpanding Through Franchising & Licensing: Opportunities and Strategies for Korean Brand in Southeast AsiaFLAsia SummitFranchise & Licensing ShowcasesFUTR CapsuleGo Global RoundtableMascot Parade

FLAsia 2026 will also feature country pavilions from Australia, Indonesia, Japan, Singapore, South Korea, Spain, Thailand, United Kingdom and Vietnam.

FLAsia Drives Industry Collaboration

The Franchising and Licensing Association (FLA) (Singapore) will mark a significant milestone at the Opening Ceremony of FLAsia 2026 with the signing of three strategic Memoranda of Understanding with Nanyang Polytechnic (NYP), Singapore Retailers Association (SRA), and Design Business Chamber Singapore (DBCS). These partnerships establish a comprehensive framework for collaboration in industry projects, internship placements, speaking opportunities, case‑study development, and the co‑development and co‑delivery of training courses for adult learners, alongside joint members’ networking and business matching events. Collectively, these initiatives will strengthen licensing adoption, foster design‑driven business growth, and equip enterprises to thrive and expand in Asia’s dynamic markets, reinforcing Singapore’s position as a hub for innovation, collaboration, and enterprise growth.

For more information on FLAsia 2026, please visit www.franchiselicenseasia.com

About Franchising & Licensing Asia (FLAsia)

Franchising & Licensing Asia (FLAsia) is Asia’s leading marketplace for franchising and licensing opportunities. Now in its 21st edition, FLAsia connects entrepreneurs, investors, franchisors, licensors and business leaders through a comprehensive platform featuring exhibitions, conferences, business matching and networking opportunities.

Held annually in Singapore, FLAsia showcases franchise concepts, licensable intellectual property, retail innovations and business expansion opportunities from around the world, enabling companies to scale across Asia through strategic partnerships and international collaboration.

Visit www.franchiselicenseasia.com for more information

About MP Singapore

The MP Group (MP) is a global full-service agency that specialises in connecting and building eco-systems, industry engagement, events management and marketing.

Established since 1987, MP embodies more than a quarter century of event building, marketing and management experience in both Eastern and Western cultures, practices, and business philosophies. We bring world-class talent, industry expertise, and incredible enthusiasm into the design and management of extraordinary online-to-offline experiences for your organisation.

MP is part of Pico Group, a global group of agencies specialising in engaging people, creating experiences and activating brands for businesses, institutions and governments. As part of the Pico group, MP has unlimited access to a wide network of industry contacts and resources. Pico Far East Holdings has been listed on the Hong Kong Stock Exchange since 1992.

Visit mpinetwork.com for more information.

About the Franchising and Licensing Association (FLA) (Singapore)

Franchising and Licensing Association (Singapore), one of the founding members of the World Franchise Council, was established in 1993 with the mission to nurture and develop Singapore’s franchising industry. An essential component of Singapore’s knowledge-based economy, FLA (Singapore) promotes and facilitates the use of franchising, licensing and branding as a growth strategy for Singapore enterprises, turning Singapore into a regional franchise and license hub.

Through its partnership with Singapore government agencies and international franchise and license bodies, FLA (Singapore) assists its members in their international development programmes. With an active growing membership of close to 180 companies, representing more than 300 strong brands, FLA (Singapore) is led and managed by a dedicated team of advisors, committee members and a full-time secretariat with the goal of supporting Singapore companies to expand internationally.

Visit www.flasingapore.org for more information.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/franchising–licensing-asia-2026-opens-new-chapter-under-mp-strengthening-singapores-position-as-asias-franchise-and-licensing-hub-302838493.html

SOURCE MP Singapore

Continue Reading

Technology

AIA Singapore expands cross-border medical access and digitalised care for more than 1 million employees

Published

on

By

 With over one-third (34%) of Singapore residents concerned over the affordability of healthcare services[1] and medical inflation projected to reach a record-high of 16.9%[2], AIA Singapore aims to bridge these cost and accessibility gaps with its upcoming corporate policy enhancements – all at no additional premium.

SINGAPORE, July 30, 2026 /PRNewswire/ — Singapore’s leading insurer in employee benefits, AIA Singapore announced today a new set of enhancements to its corporate insurance offering that will roll out from 1 August 2026 onwards. Against a backdrop of medical inflation and rising costs of healthcare, these first-in-industry enhancements are specifically designed to make quality healthcare more accessible, convenient and seamless for employees and their dependants[3].

These enhancements will protect more than 1 million corporate insured members, representing approximately one-third of Singapore’s workforce. From expanded access to professional healthcare services, to simplification of administrative processes supported by digitalisation, employees will benefit from more timely care and reduced administrative effort.

“Our latest AIA Live Better Study reveals that 34% of Singapore residents are deeply concerned about healthcare affordability, while 29% explicitly expect to spend more on medical expenses,” said Kenneth Tan, Chief Corporate Solutions Officer at AIA Singapore. “Amidst these inflationary pressures, businesses must step up to protect employee wellbeing.

By extending corporate medical access across the border into Malaysia and removing General Practitioner (GP) referral requirements at zero additional premium cost, we are directly shielding more than 1 million employees in Singapore from rising costs while streamlining their day-to-day healthcare journeys, enabling them to live Healthier, Longer, Better lives.”

Meeting today’s healthcare expectations

As healthcare utilisation continues to rise, employers face growing pressure to deliver cost-effective benefits that align with workforce needs. Simultaneously, employees expect greater flexibility in where they receive care, expanded treatment access, and on-demand digital options.

AIA Singapore’s latest enhancements directly address these dual expectations by expanding care networks and digital capabilities—all at no additional cost.

Expanding access cross-border from 1st August 2026

[Industry-First] Expanded Coverage for Inpatient Care in Malaysia: Employees with inpatient coverage can now access treatment at AIA-selected hospitals in Malaysia with a Letter of Guarantee (LOG) Plus. This cross-border extension simplifies planned treatments for employees who prefer treatment in Malaysia due to lower costs, or employees who travel frequently to Malaysia.[Industry-First] Expanded Dental Network to Malaysia: Employees with dental benefits[4] will gain access to a curated panel of dental clinics located in major Malaysian retail malls[5]. By presenting their digital AIA Dental Card, employees can enjoy routine and preventive oral healthcare with better cost certainty and no upfront payment.

Simplifying the healthcare journey

[Industry-First] GP Referral Waiver for Singapore Public Hospital Specialists: Expediting specialist clinical care, employees can visit Specialist Outpatient Clinics (SOCs) at Singapore Public Hospitals without the need for a GP referral letter from 1 August 2026 onwards. This process simplification enables more direct access for members with known or recurring conditions.

Enhancing digital access and support

Fully Digitalised Pre-Authorisation Process: Employees can also submit their pre-authorisation requests digitally anytime, anywhere through the AIA+ mobile application and web portal.Round-the-clock GP Teleconsultation with WhiteCoat: Employees can consult with a primary care doctor 24/7 via the WhiteCoat app, gaining access to expert medical advice and prescription deliveries, even during late-night hours when traditional clinics are closed.

These compelling enhancements are provided at no additional premium and apply automatically to eligible corporate policies. By improving access, simplifying processes, and expanding care options, AIA Singapore aims to boost the overall healthcare experience while helping employers and their employees maximise the value of their employee benefits programmes.

This milestone launch coincides with AIA Singapore’s 95th anniversary of protecting generations of families and businesses across the nation, reinforcing its ongoing commitment to helping individuals live Healthier, Longer, Better Lives.

– END –

About AIA   

AIA Group Limited and its subsidiaries (collectively “AIA” or the “Group”) comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets – wholly-owned branches and subsidiaries in Mainland China, Hong Kong SAR[6], Thailand, Singapore, Malaysia, Australia, Cambodia, Indonesia, Myanmar, New Zealand, the Philippines, South Korea, Sri Lanka, Taiwan (China), Vietnam, Brunei and Macau SAR[7], and a 49 per cent joint venture in India. In addition, AIA has a 24.99 per cent shareholding in China Post Life Insurance Co., Ltd.

The business that is now AIA was first established in Shanghai more than a century ago in 1919. It is a market leader in Asia (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$345 billion as of 31 December 2025.

AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia, AIA serves the holders of more than 44 million individual policies and over 16 million participating members of group insurance schemes.

AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock codes “1299” for HKD counter and “81299” for RMB counter with American Depositary Receipts (Level 1) traded on the over-the-counter market under the ticker symbol “AAGIY”.

[1] The ninth wave of the AIA Live Better Study is an independent study that was conducted from 19 December 2025 to 6 January 2026 with a sample size of 1,000 representing Singapore’s general population.

[2] ‘Medical cost inflation in Singapore set to hit record 16.9%; insurers’ body urges collective action’ 1 April 2026. Available at: https://www.straitstimes.com/singapore/health/medical-cost-inflation-in-singapore-set-to-hit-record-16-9-lia-urges-collective-action?ref=inline-article

[3] Dependants refer to eligible dependants of insured employees covered under the applicable group insurance policy.

[4] Dental refers to policies with Dental PPO (Preferred Provider Organisation) cover only.

[5] Refers to curated partner dental clinics starting in major Johor Bahru retail malls.

[6] Hong Kong SAR refers to the Hong Kong Special Administrative Region.

[7] Macau SAR refers to the Macau Special Administrative Region.

 

View original content:https://www.prnewswire.com/apac/news-releases/aia-singapore-expands-cross-border-medical-access-and-digitalised-care-for-more-than-1-million-employees-302837511.html

SOURCE AIA Singapore

Continue Reading

Trending